MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2.
3' Untranslated Regions
Antagomirs
/ genetics
Apoptosis
/ genetics
Base Sequence
Case-Control Studies
Cell Line, Tumor
Cell Movement
Cell Proliferation
Cell Survival
Gene Expression Regulation, Neoplastic
Genes, Reporter
Humans
Luciferases
/ genetics
Lung Neoplasms
/ genetics
Lymphatic Metastasis
Membrane Proteins
/ genetics
MicroRNAs
/ agonists
Molecular Mimicry
Oligoribonucleotides
/ genetics
Signal Transduction
Small Cell Lung Carcinoma
/ genetics
FLOT2
metastasis
miR-485-5p
proliferation
small cell lung cancer
Journal
Bioengineered
ISSN: 2165-5987
Titre abrégé: Bioengineered
Pays: United States
ID NLM: 101581063
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pmc-release:
05
03
2020
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
21
8
2019
Statut:
ppublish
Résumé
This study is aimed to elucidate the mechanisms underlying the role of miR-485-5p in small cell lung cancer (SCLC). The expression of miR-485-5p were quantified with real time quantitative PCR and it was found that the level of miR-485-5p was lower in SCLC tissues than normal tissues. In cultured SCLC cell lines, overexpression of miR-485-5p reduced cell proliferation, migration, and invasion in vitro, whereas knockdown of miR-485-5p performed contrary. FLOT2 expression was obviously upregulated and negatively correlated with miR-485-5p expression level in SCLC tissues. Overexpression of miR-485-5p significantly inhibited the protein expression of flotillin-2 (FLOT2) in cultured SCLC cells. Luciferase reporter assay confirmed that FLOT2 was a direct target of miR-485-5p in SCLC cells. It is concluded that miR-485-5p, as a tumor suppressor, inhibits the growth and metastasis in SCLC by targeting FLOT2. Upregulation of miR-485-5p expression may be an attractive strategy for SCLC therapy.
Identifiants
pubmed: 30836864
doi: 10.1080/21655979.2019.1586056
pmc: PMC6527069
doi:
Substances chimiques
3' Untranslated Regions
0
Antagomirs
0
MIRN485 microRNA, human
0
Membrane Proteins
0
MicroRNAs
0
Oligoribonucleotides
0
flotillins
0
Luciferases
EC 1.13.12.-
Types de publication
Journal Article
Langues
eng
Pagination
1-12Références
Curr Biol. 2003 Apr 15;13(8):686-90
pubmed: 12699627
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Cell Mol Life Sci. 2005 Oct;62(19-20):2228-40
pubmed: 16091845
Genes Dev. 2006 Mar 1;20(5):515-24
pubmed: 16510870
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Biochem J. 2007 Apr 15;403(2):313-22
pubmed: 17206938
Curr Biol. 2007 Jul 3;17(13):1151-6
pubmed: 17600709
J Cell Sci. 2009 Apr 1;122(Pt 7):912-8
pubmed: 19258392
J Cell Biol. 2010 Nov 15;191(4):771-81
pubmed: 21059848
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):551-6
pubmed: 21187433
Toxicol Appl Pharmacol. 2012 Mar 15;259(3):311-9
pubmed: 22289360
Saudi Med J. 2012 May;33(5):508-14
pubmed: 22588811
Plant Cell. 2012 May;24(5):2105-22
pubmed: 22589463
Drug Discov Today. 2013 Mar;18(5-6):282-9
pubmed: 23064097
Hepatology. 2013 Feb;57(2):840-7
pubmed: 23081718
Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19397-402
pubmed: 23132946
Curr Med Chem. 2013;20(1):4-21
pubmed: 23150999
Nat Rev Clin Oncol. 2013 Apr;10(4):235-44
pubmed: 23438759
Curr Opin Genet Dev. 2013 Feb;23(1):3-11
pubmed: 23465882
Clin Cancer Res. 2013 Oct 15;19(20):5602-12
pubmed: 23995857
J Thorac Dis. 2013 Sep;5 Suppl 4:S440-5
pubmed: 24102018
OMICS. 2014 Jan;18(1):54-64
pubmed: 24237355
JAMA. 2014 Apr 9;311(14):1430-7
pubmed: 24715074
Cancer Sci. 2014 Jul;105(7):755-62
pubmed: 24815002
Tumour Biol. 2014 Dec;35(12):12743-8
pubmed: 25227664
Cell Physiol Biochem. 2015;35(1):184-90
pubmed: 25591761
Oncotarget. 2015 May 20;6(14):12543-57
pubmed: 26002553
Cell Physiol Biochem. 2015;36(3):1186-96
pubmed: 26111756
Cell Physiol Biochem. 2015;36(3):1026-36
pubmed: 26112332
Sci Rep. 2015 Jul 24;5:11614
pubmed: 26206082
Biosci Rep. 2017 Mar 15;37(2):
pubmed: 28188157
Artif Cells Nanomed Biotechnol. 2018 Mar;46(2):224-230
pubmed: 28503944
Am J Transl Res. 2017 Jul 15;9(7):3336-3344
pubmed: 28804551
Medicine (Baltimore). 2017 Oct;96(42):e8176
pubmed: 29049199
Oncotarget. 2017 Jul 26;8(41):70084-70096
pubmed: 29050263
Nat Rev Cancer. 2017 Dec;17(12):725-737
pubmed: 29077690
Life Sci. 2018 Apr 15;199:104-111
pubmed: 29510198